首頁 > 市場調查報告書 > 製藥

感染疾病

市場調查報告書

商品編碼

1736511

2026 年至 2032 年伊波拉病毒疫苗市場（按病毒株、通路、最終用戶和地區分類）

Ebola Virus Vaccine Market By Virus Strain, Distribution Channel, End User, & Region for 2026-2032

出版日期: 2025年05月05日 | 出版商:

Verified Market Research | 英文 | 商品交期: 2-3個工作天內

價格

簡介目錄

伊波拉病毒疫苗市場評估 - 2026-2032

伊波拉病毒疫苗全球盛行率上升推動市場成長伊波拉病毒疫苗市場在 2024 年的價值為 1,143 萬美元，預計到 2032 年將成長到 9,176 萬美元，複合年成長率為 32.80%。

成長軌跡顯示市場動態呈上升趨勢。預測擴張顯示預測期內成長率強勁，2026年至2032年的複合年成長率為32.80%。

伊波拉病毒疫苗市場定義/概述

伊波拉，俗稱伊波拉出血熱，是伊波拉病毒屬的致命病毒性疾病。近年來，伊波拉已成為人類的重大威脅。該病毒通常透過動物傳播給人。

伊波拉出血熱熱是世界上最致命的凝血疾病之一，最常發生在非洲國家。此病是由出血熱病毒引起，凝血功能障礙會導致血液從體內小血管漏出，進而引發內出血。伊波拉出血熱是由伊波拉屬病毒感染引起的。

伊波拉病毒疾病 (EVD) 是一種由伊波拉病毒引起的一種嚴重且可能致命的人類疾病。伊波拉疫苗市場顯著成長，尤其是在2014-2016年西非爆發嚴重的伊波拉出血熱疫情之後，凸顯了對有效疫苗的迫切需求，以控制集體爆發並保護民眾。

伊波拉疫苗市場是全球防治未來伊波拉出血熱疫情的關鍵組成部分。政府、製藥公司、學術機構和非營利組織之間的合作正在推動伊波拉疫苗的研發、生產能力和全球分銷。市場挑戰包括確保疫苗的可負擔性和可近性（尤其是在低收入國家）、解決疫苗猶豫和虛假資訊問題，以及維持長期的生產和供應網路。

全球伊波拉疫苗市場是什麼樣的？

根據美國國家醫學圖書館記載，伊波拉出血熱疫情始於1976年。當時，疫情襲擊了蘇丹南部和剛果民主共和國北部，從6月持續到9月，持續了約四個月，死亡率分別為53%和88.1%。後來被認定為導致最初疫情爆發的兩種病毒是伊波拉病毒和薩伊伊波拉病毒。

伊波拉疫苗市場的成長與發展。首要任務是應對伊波拉出血熱疫情引發的公共衛生危機。伊波拉病毒疾病 (EVD) 對人體的毀滅性影響及其廣泛傳播的可能性凸顯了採取有效預防措施的必要性。

伊波拉疫苗市場的擴張和發展將使伊波拉疫苗成為全球衛生安全努力的重要組成部分。科學、金融、監管和地緣政治等多種力量共同推動伊波拉疫苗市場的擴張和發展。

伊波拉疫苗市場面臨哪些挑戰？

目前對伊波拉疫苗的需求主要源於疫情應對，因為疫情的不可預測性以及疾病集中在衛生資源有限的中低收入國家等變數阻礙了大規模疫苗接種計劃的實施。

疫苗的研發和生產成本高昂，這可能導致疫苗價格高昂，並限制資源貧乏、疫情最容易發生的地區的疫苗供應和可近性。

物流挑戰包括在基礎設施匱乏的偏遠地區分發和儲存疫苗，以及在供應鏈中維持這些疫苗接種所需的低溫運輸條件，這增加了新的複雜性。

伊波拉病毒疫苗的嚴格監管授權可能會嚴重阻礙市場擴張。監管要求可能會推遲新疫苗的上市，並阻礙新業務進入市場。疫苗研發和商業化的核准時間和成本的增加可能會限制市場成長。資源有限的小型企業可能難以遵守嚴格的法規，這些法規要求疫苗必須進行全面的臨床試驗、安全評估和生產。監管壁壘可能會阻礙伊波拉病毒疫苗的商業化和供應，從而阻礙市場成長。

Ebola is one of the world's most deadly diseases caused by blood coagulation. It most typically occurs in African countries. It is characterized as a haemorrhagic fever virus because of the coagulation issues that lead to internal bleeding when blood pours from small blood vessels in the body. It is caused by an infection with viruses from the Ebolavirus genus.

Ebola virus disease (EVD) is a serious and frequently fatal sickness in humans caused by the Ebola virus. The market for Ebola vaccines has grown significantly, particularly after the serious Ebola outbreak in West Africa from 2014 to 2016, which emphasized the critical need for effective vaccines to manage outbreaks and protect populations.

The Ebola virus vaccine market is an important part of global efforts to prevent and control future outbreaks of the illness. Collaborations among governments, pharmaceutical corporations, academic institutions, and non-profit groups are driving Ebola virus vaccine development, manufacturing capacity and global distribution. Market challenges include assuring vaccine price and accessibility, particularly in low-income countries, tackling vaccination hesitancy and disinformation, and maintaining long-term manufacturing and supply networks.

What was the global Outbreaks of Ebola Virus Vaccine Market?

According to the National Library of Medicine, the outbreak occurred in the year 1976. It struck southern Sudan and the northern part of the Democratic Republic of Congo and lasted for about four months, lasting from June to September, with a mortality rate of 53% and 88.1%, respectively. The two viruses that were later identified and held accountable for the first outbreak were Sudan ebolavirus and Zaire ebolavirus.

The growth and development of the Ebola virus vaccine market. The most important requirement is to handle the public health crisis caused by Ebola epidemics. The destructive effects of Ebola virus disease (EVD) on human health, as well as its potential for broad transmission, highlight the need for effective preventive measures.

The expansion and development of the Ebola virus vaccine market, establishing it as an essential component of global health security efforts. The combination of scientific, financial, regulatory, and geopolitical forces emphasizes the strong drivers propelling.

What are the Challenges Faced by the Ebola Virus Vaccine Market?

The current demand for Ebola vaccinations is mostly driven by outbreak response efforts. Widespread vaccination programs have yet to be undertaken due to variables such as the unexpected nature of outbreaks and the concentration of illnesses in low and middle income countries with limited medical resources.

High costs for developing and manufacturing vaccinations are costly operations. This can result in high vaccine pricing, thereby limiting affordability and accessibility in resource-constrained areas most vulnerable to epidemics.

Logistical challenges include distributing and storing vaccines in remote places with little infrastructure. Maintaining the requisite cold chain conditions for these vaccinations along the supply chain adds a new level of complication.

Stringent regulatory licensing for Ebola virus vaccines might severely impede market expansion. Regulatory requirements can slow the launch of new vaccinations and prevent new businesses from entering the market. Increasing approval time and expenses for vaccine development and commercialization may restrict market growth. Small enterprises with limited resources may struggle to comply with tight laws, which require comprehensive clinical trials, safety evaluations, and manufacturing requirements. Regulatory barriers might impede the commercialization and availability of Ebola virus vaccines, hindering market growth.

Category-Wise Acumens

How the Vesicular Stomatitis Virus Platform has emerged in Ebola Virus Vaccine Market?

In the Ebola virus vaccine the vesicular stomatitis virus (rVSV) platform has emerged as a dominant force and is rapidly expanding. The rVSV platform makes use of a genetically modified vesicular stomatitis virus, with the surface glycoprotein replaced by that of the Ebola virus. In clinical trials, this platform showed encouraging findings, including high effectiveness and the potential to induce powerful immune responses against Ebola virus infection.

Accine platforms, such as animal adenovirus type 3 (ChAd3) and adenovirus serotype 26 (Ad26), are also making progress in the sector. ChAd3 and Ad26 vaccines use adenovirus vectors to transmit genetic material encoding Ebola virus antigens, thereby inducing an immune response. These systems have shown efficacy and safety characteristics in clinical trials and are being investigated as potential replacements or complementing vaccines to the rVSV platform.

The Ebola virus vaccine market the rVSV platform presently leading. The ChAd3 and Ad26 platforms are also rapidly expanding and offer intriguing options in the search for effective Ebola virus vaccines. Continued research and development across many vaccine platforms is critical to addressing the complex challenges posed by Ebola virus infection and ensuring the availability of viable vaccines for future outbreaks.

How the Hospitals & Government Suppliers contain the supreme for several reasons for in Ebola Virus Vaccine Market?

The supreme for several reasons for Ebola Virus Vaccine the Hospitals and Government Suppliers this route is dominant for numerous reasons. Ebola outbreaks typically occur in areas with limited access to retail pharmacies. Because of the vaccines particular storage requirements (cold chain maintenance) hospitals and government entities have the facility and competence to handle them properly. Finally, during outbreaks, governments frequently coordinate vaccination programs, making them key distributors.

The Ebola vaccine market is likely to be limited position but online pharmacies are a fast-increasing part of the pharmaceutical industry. The aforementioned cold chain requirements, combined with the fact that Ebola vaccines are typically utilized during outbreaks (rather than for normal injections), make online pharmacies an unsuitable alternative.

How Vaccines and Healthcare Industries are increasing in North America by Ebola Virus Vaccine Market?

The increasing development of vaccines and pharmaceuticals in the healthcare industry, as well as the presence of leading pharmaceutical companies in North America, the market in this region is expected to rise significantly throughout the forecast period.

North America, especially the United States, has a booming pharmaceutical industry distinguished by cutting-edge R&D infrastructure, modern manufacturing capabilities and a favourable regulatory framework. The region is home to several renowned pharmaceutical corporations, including Pfizer, Johnson & Johnson, Merck & Co., and Moderna, among others, which are constantly investing in breakthrough medication discovery and development projects.

North America is expected to benefit from rapid expansion in the healthcare business. The region's premier pharmaceutical businesses, combined with ongoing investments in R&D and technical innovation, will propel healthcare forward and contribute to the region's status as a global pharmaceutical powerhouse.

How the Ebola virus vaccine market Present in Asia-Pacific?

The Ebola virus vaccine market in the Asia Pacific is a complex environment with many elements influencing its development and accessibility. Historically, the region has had less direct exposure to Ebola outbreaks than regions such as Africa, but concerns about the virus's potential spread and the need for preparedness have motivated increased focus on vaccine development and deployment.

The Asia Pacific area is distinguished by country-specific variations in healthcare infrastructure and resources. While some countries have advanced healthcare systems and research capacities, others confront severe challenges such as limited budget, inadequate infrastructure, and a healthcare manpower shortage. These obstacles can stymie vaccine research efforts and restrict access to immunizations in impoverished communities.

Asia Pacific offers chances for innovation and collaboration in the Ebola virus vaccination industry. As the region's healthcare infrastructure and research capacity improve, there is an opportunity for increased investment in vaccine development and distribution. Furthermore, addressing health inequities and ensuring fair access to vaccines will be critical to effectively managing possible Ebola outbreaks throughout Asia Pacific.

Competitive Landscape

The Ebola virus vaccine market industry companies use numerous tactics such as collaborations, acquisitions, mergers, and partnerships to establish a global presence and remain competitive. Please note that the company profile section includes both commercially available drugs and those in clinical development.

The Ebola Virus Vaccine Market study report will provide valuable insight with an emphasis on the global market. The major players in the market include:

Sarepta Therapeutics

Mapp Biopharmaceutical

Regeneron Pharmaceuticals, Inc.

GlaxoSmithKline plc.

Novavax, Inc.

GeoVax

Tekmira Pharmaceuticals

NewLink Genetics Corporation,

Bavarian Nordic

Merck & Co., Inc.

Johnson & Johnson.

Latest Developments

In October 2022, Merck & Co. will manufacture and give an investigational Sudan ebolavirus vaccine to a global non-profit organization's research program in Uganda, which is experiencing an outbreak.

In November 2021, the University of Oxford began phase one of its studies, evaluating the vaccine on human volunteers. In phase one of the studies, 26 participants aged 18 to 55 will get a single dose of the ChAdOx1 biEBOV Ebola vaccine at the university. They will subsequently be studied for six months, with the results expected in the second quarter of 2022.

In July 2020, Johnson & Johnson gained European Commission approval for an Ebola vaccine regimen for the prevention of Ebola Virus disease. The company's plan approval allows for collaboration with the World Health Organization (WHO) on vaccine pre-qualification, resulting in faster registration of its Ebola vaccine in African nations and a stronger market position.

1 INTRODUCTION OF GLOBAL EBOLA VIRUS VACCINE MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL EBOLA VIRUS VACCINE MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL EBOLA VIRUS VACCINE MARKET, BY VIRUS STRAIN

5.1 Overview
5.2 Recombinant Vesicular Stomatitis Virus
5.3 Chimpanzee Adeno Virus Type 3
5.4 Adeno Virus Serotype 26

6 GLOBAL EBOLA VIRUS VACCINE MARKET, BY DISTRIBUTION CHANNEL

6.1 Overview
6.2 Hospital & Retail Pharmacies
6.3 Online Pharmacies
6.4 Government suppliers
6.5 Others

7 GLOBAL EBOLA VIRUS VACCINE MARKET, BY END USER

7.1 Overview
7.2 Hospital
7.3 Homecare
7.4 Specialty Clinics
7.5 Ambulatory Surgical Centres
7.6 Others

8 GLOBAL EBOLA VIRUS VACCINE MARKET, BY GEOGRAPHY

8.1 Overview
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.2.3 Mexico
8.3 Europe
- 8.3.1 Germany
- 8.3.2 U.K.
- 8.3.3 France
- 8.3.4 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Rest of Asia Pacific
8.5 Rest of the World
- 8.5.1 Latin America
- 8.5.2 Middle East & Africa

9 GLOBAL EBOLA VIRUS VACCINE MARKET COMPETITIVE LANDSCAPE

9.1 Overview
9.2 Company Market Ranking
9.3 Key Development Strategies

10 COMPANY PROFILES

10.1 Sarepta Therapeutics
- 10.1.1 Overview
- 10.1.2 Financial Performance
- 10.1.3 Product Outlook
- 10.1.4 Key Developments
10.2 Mapp Biopharmaceutical
- 10.2.1 Overview
- 10.2.2 Financial Performance
- 10.2.3 Product Outlook
- 10.2.4 Key Developments
10.3 Regeneron Pharmaceuticals, Inc.
- 10.3.1 Overview
- 10.3.2 Financial Performance
- 10.3.3 Product Outlook
- 10.3.4 Key Developments
10.4 GlaxoSmithKline plc.
- 10.4.1 Overview
- 10.4.2 Financial Performance
- 10.4.3 Product Outlook
- 10.4.4 Key Developments
10.5 Novavax, Inc.
- 10.5.1 Overview
- 10.5.2 Financial Performance
- 10.5.3 Product Outlook
- 10.5.4 Key Developments
10.6 GeoVax
- 10.6.1 Overview
- 10.6.2 Financial Performance
- 10.6.3 Product Outlook
- 10.6.4 Key Developments
10.7 Tekmira Pharmaceuticals
- 10.7.1 Overview
- 10.7.2 Financial Performance
- 10.7.3 Product Outlook
- 10.7.4 Key Developments
10.8 NewLink Genetics Corporation
- 10.8.1 Overview
- 10.8.2 Financial Performance
- 10.8.3 Product Outlook
- 10.8.4 Key Developments
10.9 Bavarian Nordic
- 10.9.1 Overview
- 10.9.2 Financial Performance
- 10.9.3 Product Outlook
- 10.9.4 Key Developments
10.10 Merck & Co., Inc.
- 10.10.1 Overview
- 10.10.2 Financial Performance
- 10.10.3 Product Outlook
- 10.10.4 Key Developments